EXACT Sciences (NASDAQ: EXAS) and BTG (OTCMKTS:BTGGF) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.
This is a breakdown of recent ratings and recommmendations for EXACT Sciences and BTG, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
82.6% of EXACT Sciences shares are held by institutional investors. 4.0% of EXACT Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
EXACT Sciences has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, BTG has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Valuation and Earnings
This table compares EXACT Sciences and BTG’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EXACT Sciences||$265.99 million||23.43||-$114.39 million||($0.99)||-51.64|
BTG has lower revenue, but higher earnings than EXACT Sciences.
This table compares EXACT Sciences and BTG’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
EXACT Sciences beats BTG on 6 of the 9 factors compared between the two stocks.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
BTG Company Profile
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and interventional pulmonology products, including PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Specialty Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of envenomations from the copperhead snake; Vistogard for the treatment of 5-fluorouracil toxicity; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup for hip joint replacement; and Lemtrada for treatment of multiple sclerosis. The company also manufactures and commercializes therapeutic ultrasound devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.